MARKET

BMRN

BMRN

Biomarin Pharmaceutical Inc
NASDAQ
51.77
-0.35
-0.67%
After Hours: 51.77 0 0.00% 18:09 12/16 EST
OPEN
52.34
PREV CLOSE
52.12
HIGH
52.49
LOW
51.47
VOLUME
1.92M
TURNOVER
--
52 WEEK HIGH
73.51
52 WEEK LOW
50.76
MARKET CAP
9.95B
P/E (TTM)
19.40
1D
5D
1M
3M
1Y
5Y
1D
1 Oversold Stock Primed to Rebound and 2 That Underwhelm
Barchart · 19h ago
Do Options Traders Know Something About BMRN Stock We Don't?
NASDAQ · 1d ago
Weekly Report: what happened at BMRN last week (1208-1212)?
Weekly Report · 1d ago
Stifel Nicolaus Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN)
TipRanks · 2d ago
Should BioMarin’s Cost Cuts, Roctavian Exit, and Pipeline Shifts Require Action From BMRN Investors?
Simply Wall St · 2d ago
BioMarin (BMRN): Has the Market Overreacted to This Year’s Pullback in a Profitable Rare-Disease Leader?
Simply Wall St · 4d ago
Does The Market Misprice BioMarin After 2025 DCF And Earnings Multiple Signals?
Simply Wall St · 6d ago
Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?
Seeking Alpha · 12/08 19:46
More
About BMRN
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.

Webull offers Biomarin Pharmaceutical Inc stock information, including NASDAQ: BMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMRN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMRN stock methods without spending real money on the virtual paper trading platform.